Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Significant Increase in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 1,688,500 shares, a growth of 90.3% from the October 31st total of 887,500 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 16,885.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

BIOVF remained flat at $27.23 during trading on Friday. Swedish Orphan Biovitrum AB has a 1-year low of $22.40 and a 1-year high of $32.25. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73. The company has a fifty day simple moving average of $30.21 and a two-hundred day simple moving average of $27.89.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.